title: Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.
abstract: Successful vaccine development against HIV will likely require the induction of strong, long-lasting humoral and cellular immune responses in both the systemic and mucosal compartments. Based on the known immunological linkage between the upper-respiratory and urogenital tracts, we explored the potential of nasal adjuvants to boost immunization for the induction of vaginal and systemic immune responses to gp140. Mice were immunized intranasally with HIV gp140 together with micellar and emulsion formulations of a synthetic TLR4 agonist, Glucopyranosyl Lipid Adjuvant (GLA) and responses were compared to R848, a TLR7/8 agonist, or chitosan, a non TLR adjuvant. GLA and chitosan but not R848 greatly enhanced serum immunoglobulin levels when compared to antigen alone. Both GLA and chitosan induced high IgG and IgA titers in nasal and vaginal lavage and feces. The high IgA and IgG titers in vaginal lavage were associated with high numbers of gp140-specific antibody secreting cells in the genital tract. Whilst both GLA and chitosan induced T cell responses to immunization, GLA induced a stronger Th17 response and chitosan induced a more Th2 skewed response. Our results show that GLA is a highly potent intranasal adjuvant greatly enhancing humoral and cellular immune responses, both systemically and mucosally.
authors: Centre for Infection and Immunity, St. George's University of London, London, United Kingdom.
authors: Mauricio A
authors: MA
authors: Arias
authors: Griet A
authors: GA
authors: Van Roey
authors: John S
authors: JS
authors: Tregoning
authors: Magdalini
authors: M
authors: Moutaftsi
authors: Rhea N
authors: RN
authors: Coler
authors: Hillarie P
authors: HP
authors: Windish
authors: Steven G
authors: SG
authors: Reed
authors: Darrick
authors: D
authors: Carter
authors: Robin J
authors: RJ
authors: Shattock
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000281:Administration, Intranasal; D000818:Animals; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009297:Nasal Mucosa / Q000276:immunology*; D051197:Toll-Like Receptor 4 / Q000819:agonists*; D054299:env Gene Products, Human Immunodeficiency Virus / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; C493487:Tlr4 protein, mouse; D051197:Toll-Like Receptor 4; D054299:env Gene Products, Human Immunodeficiency Virus; C097729:gp140 envelope protein, Human immunodeficiency virus 1